Biotech

Before scaling a biotech strategy, I want to see a legible evidence chain, a realistic operational plan for the next study or assay expansion, and a regulatory path that has been thought about early enough to influence the design work.

The signals I care about are reproducibility of the evidence package, time from milestone to next decision, and readiness for study startup or scale-up. Those metrics reveal whether a team is generating knowledge or only generating slides. Before scaling a biotech strategy, I want to see a legible evidence chain, a realistic operational plan for the next study or assay expansion, and a regulatory path that has been thought about early enough to influence the design work.

The clearest signals usually live in credibility of the evidence package, alignment between science and operating plan, and clarity of the regulatory path ahead. A good archive helps future-you compare decisions over time instead of restarting each month from a vague sense that things are improving.

Keep these nearby while you evaluate:
- scverse: scverse.org/
A strong starting point for open computational work in modern omics analysis.
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.